On November 15, Pfizer’s adalimumab product became the 25th biosimilar approved by FDA under the Biologics Price Competition and Innovation Act (BPCIA). The road to the 25th approval has been long and has involved some of the biggest companies and medications in the pharmaceutical industry. In this post, we take a brief look at how we got here, where things stand for the 25 approved biosimilars, and where we are headed next.
Steve Keane is of counsel in the firm’s Intellectual Property Group. Mr. Keane focuses his practice on patent litigation, with an emphasis on life sciences. Combining his extensive experience as a scientist with years of patent practice and a deep understanding of industry, Mr. Keane advises clients on a wide variety of patent matters and on all phases of patent litigation. He has litigated BPCIA, More ›